PARP14 and neoplasm: Ribon Therapeutics are studying the effects of their ARTD8 inhibitors: in vitro data showed that ARTD8 plays an immune-suppressive role in the tumor microenvironment, suggesting that ARTD8 targeting could generate an anti-cancer inflammatory response, similarly to results obtained by means of checkpoint inhibition [123,124,125,126,127,128,129].